19 completed or ongoing clinical trials. In Phase I/II clinical trials of crenolanib combined with intensive chemotherapy in patients with relapsed or refractory and newly diagnosed FLT3-mutated acute myeloid leukemia, or AML, composite complete remission has been observed in 68% and 85% of patients, respectively, as evidenced by the reduction in leukemic blasts to less than or equal to 5% in the bone marrow. Based on these results, we have commenced two pivotal Phase III clinical trials of crenolanib in FLT3-mutated AML: one trial in relapsed or refractory patients, and another trial in newly diagnosed patients. Both of these ongoing clinical trials enrolled the first patient in August 2018. In addition to its observed activity in FLT3, in preclinical studies, crenolanib has also been observed to be a highly potent inhibitor of platelet-derived growth factor, or PDGF, receptors, and is being evaluated in several solid tumor indications where PDGF pathways are implicated as disease drivers. Given the compelling safety and clinical benefit observed thus far, we believe crenolanib has the potential to become a best-in-class therapeutic for multiple oncology indications. Our vision is to prolong the lives of cancer patients by advancing crenolanib in combination with standard of care chemotherapies as well as emerging therapies that offer the potential for synergistic treatment effects. In certain diseases which currently have no approved treatments, crenolanib is being evaluated as monotherapy.